Integer Holdings Co. (NYSE:ITGR) Receives Consensus Rating of “Moderate Buy” from Analysts

Integer Holdings Co. (NYSE:ITGR) has been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $145.44.

Several research analysts have issued reports on ITGR shares. Citigroup raised their price objective on shares of Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a research report on Wednesday, December 11th. KeyCorp raised their price target on Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. Benchmark upped their price objective on Integer from $130.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Wells Fargo & Company reiterated an “overweight” rating and issued a $160.00 target price on shares of Integer in a research note on Tuesday, December 3rd. Finally, Truist Financial upped their price target on Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th.

Hedge Funds Weigh In On Integer

A number of hedge funds have recently made changes to their positions in ITGR. Contravisory Investment Management Inc. increased its position in Integer by 55.9% during the 3rd quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 80 shares in the last quarter. Huntington National Bank raised its stake in shares of Integer by 8,933.3% in the 3rd quarter. Huntington National Bank now owns 271 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 268 shares during the period. Quest Partners LLC lifted its holdings in shares of Integer by 3,688.9% during the 2nd quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 332 shares in the last quarter. GAMMA Investing LLC boosted its position in Integer by 74.1% during the 3rd quarter. GAMMA Investing LLC now owns 653 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 278 shares during the period. Finally, Larson Financial Group LLC increased its holdings in Integer by 20,000.0% in the 3rd quarter. Larson Financial Group LLC now owns 1,005 shares of the medical equipment provider’s stock valued at $131,000 after purchasing an additional 1,000 shares in the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Trading Up 0.8 %

Shares of ITGR stock opened at $135.88 on Friday. Integer has a fifty-two week low of $94.56 and a fifty-two week high of $142.76. The company has a 50 day moving average price of $134.50 and a 200 day moving average price of $126.51. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.09 and a current ratio of 3.28. The stock has a market capitalization of $4.56 billion, a P/E ratio of 41.94, a price-to-earnings-growth ratio of 2.02 and a beta of 1.12.

Integer (NYSE:ITGR) last announced its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share for the quarter, beating analysts’ consensus estimates of $1.36 by $0.07. Integer had a net margin of 6.70% and a return on equity of 11.63%. The business had revenue of $431.42 million for the quarter, compared to analyst estimates of $440.59 million. During the same period last year, the business earned $1.27 EPS. The company’s revenue was up 8.7% on a year-over-year basis. Equities research analysts predict that Integer will post 5.33 EPS for the current fiscal year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.